CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Understanding what constitutes a good retirement fund at age 40 is essential. Start evaluating your savings for a secure retirement.
15,836 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A surge of headlines about aliens and the Catholic Church is reshaping how investors think about religion, charity, a...
When a mining stock pops today, investors sit up. Discover the drivers behind SSR Mining's rally, what it means for r...
Three crypto wallets booked $24.25 million in World Cup bets before routing proceeds to one Binance address, triggeri...
A bold government push is reshaping quantum tech and investing. Learn which three big stocks are positioned to win, a...
Strategy’s perpetual preferred stock has fallen from the $100 issuance price to the mid-$70s, prompting widespread in...
Strategy's latest plan more has traders watching Bitcoin's moves closely. This article breaks down what the plan mean...
The NEOS SPY 500 High Income ETF, about $6.9B in assets, continues to pay monthly dividends around a 12% yield throug...
Two physical silver ETFs track the LBMA price, but a fee gap and liquidity differences drive the decision on which to...
As Netflix prepares to report earnings after the bell, investors are dialed in on one question that could shape the s...
When memory stocks spark market optimism, chipmakers can drive broader gains. This piece breaks down what’s behind th...
A new wave could lift fix-and-flip and BRRRR strategies in 2026. This guide shows how excited investors—home flipping...